Effects of host factors, virulent starins, and bacteriophage on therapies of Clostridium difficile infection including fecal microbiota transplantation

Effects of host factors, virulent starins, and bacteriophage on therapies of Clostridium difficile infection including fecal microbiota transplantation - Host factors, virulent starins, and phage against Clostridium difficile infection therapy

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021126

Enrollment

Registered

2016-02-22

Start date

2016-02-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Clostridium difficile infection

Interventions

fecal microbiota transplantation

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with symptomatic Clostridium difficile infection treated by vancomycin

Exclusion criteria

Exclusion criteria: 1)Allergy to drugs used 2)Pregnant or probably pregnant women 3)Patients who are considered unsuitable by doctors

Design outcomes

Primary

Measure	Time frame
Pre-treatment differences of Clostridium difficile strains(toxinA/B, binary toxin, PCR-ribotype) among vancomycin-sensitive, FMT-sensitive, and FMT-resistant groups	—

Secondary

Measure	Time frame
1. Pre-treatment differences of host factors and phages among vancomycin-sensitive, FMT-sensitive, and FMT-resistant groups 2. Changes of Clostridium difficile strains(toxinA/B, binary toxin, PCR-ribotype) and phages 8 and 24 weeks after FMT	—

Countries

Japan

Contacts

Public ContactNaoki Ohmiya

Fujita Health University Department of Gastroenterology

nohmiya@fujita-hu.ac.jp0562-93-9240

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026